Crescent Biopharma (CBIO) vs Evolus (EOLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evolus (EOLS) has outperformed Crescent Biopharma (CBIO) over the past year, gaining 23.6% versus a gain of 19.5%. Over five years, EOLS leads with a +0.9% price change compared with -93.2% for CBIO. Crescent Biopharma is the larger company by market cap ($523.8 million vs $506.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | EOLS |
|---|---|---|
| Share price | $14.10 | $7.67 |
| Market cap | $523.77M | $506.61M |
| 1-day change | +4.52% | -0.90% |
| YTD return | +13.74% | +16.39% |
| 1-year return | +19.49% | +23.64% |
| 5-year return | -93.19% | +0.91% |
| Forward P/E | — | 26.22 |
| EPS (TTM) | $-7.63 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.41 | $9.31 |
| 52-week low | $8.72 | $3.86 |
| Distance from 52-week high | -48.56% | -17.62% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +123.40% | +95.57% |
| Average volume | 397.58K | 896.67K |
| Shares outstanding | 37.14M | 66.05M |
| Employees | 69 | 353 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 353 employees
CBIO vs EOLS FAQ
Which is bigger, Crescent Biopharma or Evolus?
Crescent Biopharma (CBIO) is larger, with a market capitalization of $523.77M compared with $506.61M for Evolus (EOLS).
Which stock has performed better over the past year, CBIO or EOLS?
EOLS returned +23.64% over the past 12 months, compared with +19.49% for CBIO (price return, excluding dividends). Past performance does not predict future results.
Are Crescent Biopharma and Evolus in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.